Advertisement
Advertisement

P&G lifts sales forecast as price hikes, hygiene product demand continue

By:
Reuters
Updated: Jan 19, 2022, 14:22 GMT+00:00

(Reuters) - Procter & Gamble Co beat quarterly sales estimates on Wednesday, as the consumer goods giant benefited from higher prices and resurgent demand for cleaning products due to a spike in COVID-19 infections.

The logo for Procter & Gamble Co. is displayed on a screen on the floor of the NYSE in New York

(Reuters) -Procter & Gamble bumped up its annual sales forecast on Wednesday, as the consumer goods giant benefits from higher prices and resurgent cleaning products demand amid a spike in COVID-19 infections.

The company’s shares rose nearly 2% in premarket trading as strong quarterly sales helped cushion the blow from a bigger-than-previously forecast increase in annual freight and commodity costs.

Sales of fabric & home care products, including Tide and Mr. Clean, rose 7% in the second quarter, as the rapid spread of the Omicron coronavirus variant led consumers to buy more cleaning products.

A more intense flu season also drove organic demand for personal health care products up 20%.

This, along with price hikes to offset higher commodity and freight costs, boosted net sales by 6% to $20.95 billion. Analysts had expected $20.34 billion, according to Refinitiv IBES data.

Inflationary pressures are expected to continue for a while, P&G’ finance chief said after the company forecast a hit of $2.8 billion from commodity, freight and foreign exchange headwinds this year, up from $2.3 billion expected earlier.

P&G also raised its fiscal 2022 organic sales growth forecast to between 4% and 5%, from 2% and 4% earlier, and said it would buy back $9 billion to $10 billion worth of shares, compared with $7 billion to $9 billion expected earlier.

P&G also eased speculation that it could be interested in buying GlaxoSmithKline’s consumer health business, which has drawn interest from European peer Unilever.

In a CNBC interview, CEO Jon Moeller said he was “very happy with its current portfolio” and saw no need for a large acquisition.

On Saturday, GSK rejected Unilever’s $68.4 billion offer for its consumer arm, calling it undervalued and saying it would stick to plans for a separate listing of the entity this year.

(Reporting by Uday Sampath and Siddharth Cavale in Bengaluru; Editing by Maju Samuel)

About the Author

Reuterscontributor

Reuters, the news and media division of Thomson Reuters, is the world’s largest international multimedia news provider reaching more than one billion people every day. Reuters provides trusted business, financial, national, and international news to professionals via Thomson Reuters desktops, the world's media organizations, and directly to consumers at Reuters.com and via Reuters TV. Learn more about Thomson Reuters products:

Advertisement